SCHEMBL4816461

SCHEMBL4816461

CCOC(=O)c1cc2c(ccc3[nH]ncc32)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.53
ALDH1A1 P00352 5/20 0.53
RAB9A P51151 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
HPGD P15428 3/20 0.53
HSD17B10 Q99714 1/20 0.53
NPC1 O15118 3/20 0.50
LMNA P02545 3/20 0.50
HTT P42858 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
MMP13 P45452 7/20 0.49
MMP2 P08253 5/20 0.49
MMP14 P50281 3/20 0.49
MAPT P10636 3/20 0.49
GAA P10253 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
GLA P06280 1/20 0.49
ATM Q13315 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4808311 0.83 KDM4E (0.53) KDM4EALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL4810186 0.78 KDM4E (0.55) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL31081095 0.78 GABRA1 (0.44) KDM4EALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL6739125 0.77 KDM4E (0.58) KDM4EALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL6518295 0.77 KDM4E (0.64) KDM4EALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL29705922 0.77 AURKA (0.46) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL7954222 0.75 ALOX15 (0.57) KDM4EALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL4404148 0.75 KDM4E (0.56) KDM4EALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL5780732 0.75 KDM4E (0.56) KDM4EALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL17429439 0.75 KDM4E (0.56) KDM4EALDH1A1RAB9ASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7378431-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-05-27 US disclosed
US-7375116-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-05-20 US disclosed
US-7365083-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-04-29 US disclosed
US-7361670-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-04-22 US disclosed
US-20050159451-A1 Amide derivatives as NMDA receptor antagonists HORVATH CSILLA (HU) 2005-07-21 US disclosed
US-6919355-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2005-07-19 US disclosed
US-20050113359-A1 Amide derivatives as NMDA receptor antagonists HORVATH CSILLA (HU) 2005-05-26 US disclosed
US-20050113361-A1 Amide derivatives as NMDA receptor antagonists HORVATH CSILLA (HU) 2005-05-26 US disclosed
US-20050113360-A1 Amide derivatives as NMDA receptor antagonists HORVATH CSILLA (HU) 2005-05-26 US disclosed
US-20030199552-A1 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. 2003-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113361-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2B KDM4E 934/4885ALDH1A1 3399/4885RAB9A 4407/4885
US-20050113360-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2B KDM4E 1346/4885ALDH1A1 3195/4885RAB9A 3666/4885
US-20050159451-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2B KDM4E 1242/4885ALDH1A1 3627/4885RAB9A 4443/4885
US-20050113359-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2B KDM4E 885/4885ALDH1A1 3307/4885RAB9A 4391/4885
US-20030199552-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2C KDM4E 1215/4885ALDH1A1 1852/4885RAB9A 4308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.